AADI - Aadi Bioscience, Inc.
2.73
0 0%
Share volume: 1,740
Last Updated: Wed 05 Feb 2025 12:00:04 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.61%
PREVIOUS CLOSE
CHG
CHG%
$2.73
0.00
0.00%
Fundamental analysis
36%
Profitability
35%
Dept financing
23%
Liquidity
75%
Performance
30%
Performance
5 Days
-5.21%
1 Month
-19.94%
3 Months
37.19%
6 Months
97.83%
1 Year
60.59%
2 Year
-78.26%
Key data
Stock price
$2.73
DAY RANGE
$2.73 - $2.73
52 WEEK RANGE
$1.21 - $3.81
52 WEEK CHANGE
$56.00
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Neil P. Desai
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: aadibio.com
Employees: 40
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin.
Recent news